Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug-drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI-related parameters have often been considered a limitation for predicting PBPK-DDIs. Sensitivity analysis (SA) around DDI input parameters using PBPK analysis is often applied for assessing the relevance of clinical DDI predictions/prioritization/study designs. This perspective aims to explore and advocate practical approaches for precipitant (inhibitor/inducer) PBPK-DDI SA for optimal clinically relevant evaluations.
Authors
- Pradeep Kumar Sharma (ORCID: https://orcid.org/0000-0003-3415-8917)
- Karen Rowland Yeo (ORCID: https://orcid.org/0000-0002-7020-1970)
- Kunal S. Taskar (ORCID: https://orcid.org/0000-0001-9979-8267)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Age UK (GB)
- Certara (United States) (US)
- AstraZeneca (Poland) (PL)
Publication Details
- Journal
- Clinical Pharmacology & Therapeutics
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1002/cpt.70127
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca